2-(氨基甲基)-3-吡啶醇 | 194665-89-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(氨基甲基)-3-吡啶醇
• 中文别名: 2-(氨基甲基)吡啶-3-醇
• 英文名称: 2-aminomethyl-3-hydroxypyridine
• 英文别名: 3-Hydroxy-2-aminomethyl-pyridin；2-aminomethyl-pyridin-3-ol；2-(Aminomethyl)pyridin-3-ol
• CAS: 194665-89-9
• 化学式: C₆H₈N₂O
• mdl: MFCD01217253
• 分子量: 124.142
• InChiKey: DMFOVOSDFLKXRW-UHFFFAOYSA-N

物化性质

• 沸点：
  355.9±27.0 °C(Predicted)
• 密度：
  1.228±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  59.1
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  双(2-氯乙基)氨基磷酰二氯 、 2-(氨基甲基)-3-吡啶醇 在 三乙胺 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 以90%的产率得到Bis-(2-chloro-ethyl)-(2-oxo-3,4-dihydro-2H-1-oxa-3,5-diaza-2λ⁵-phospha-naphthalen-2-yl)-amine
  参考文献：
  名称：

  Syntheses of Ortho-Aminomethylpyridinols and Oxazaphosphorino[m,n-x]pyridines.

  摘要：

  Oxazaphosphorino[m,n-x]pyridines compounds have been prepared by condensation of methyl dichlorophosphate with ortho-aminomethylpyridinols.

  DOI：

  10.1080/00397919708004997
• 作为产物：
  描述：

  3-羟基吡啶-N-氧化物 在 palladium on activated charcoal 氨 、 氢气 、 三乙胺 作用下， 以 乙醇 、 乙腈 为溶剂， 45.0~110.0 ℃ 、303.98 kPa 条件下， 反应 14.0h， 生成 2-(氨基甲基)-3-吡啶醇
  参考文献：
  名称：

  Syntheses of Ortho-Aminomethylpyridinols and Oxazaphosphorino[m,n-x]pyridines.

  摘要：

  Oxazaphosphorino[m,n-x]pyridines compounds have been prepared by condensation of methyl dichlorophosphate with ortho-aminomethylpyridinols.

  DOI：

  10.1080/00397919708004997

文献信息

• [EN] TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS<br/>[FR] INHIBITEURS DE KARS DÉPENDANT D'AKR1C3 TRICYCLIQUES
  申请人：NOVARTIS AG

  公开号：WO2021005586A1

  公开（公告）日：2021-01-14

  The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.

  本发明涉及新型三环化合物，这些化合物是AKR1C3依赖的KARS抑制剂，涉及其制备方法、药物组合物、含有它们的药物以及它们在由AKR1C3依赖的KARS抑制剂介导的疾病和疾患中的应用。
• Process for Preparing 6,7-Dihydro-5H-Imidazo[1,5-A]Pyridin-8-One
  申请人：Martin Pierre

  公开号：US20090118512A1

  公开（公告）日：2009-05-07

  6,7-Dihydro-5H-imidazo[1,5-a]pyridin-8-one (I), is obtainable in high yields by: 1) a process which proceeds from a suitably protected C-(3-hydroxypyridin-2-yl)methylamine whose amine is converted to the formamide which is then cyclized to the imidazo[1,5-a]pyridine and hydrogenated to the 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one, and suitably protected C-(3-hydroxypyridin-2-yl)methylamines can be prepared either in 2 steps proceeding from commercially available 3-hydroxy-2-cyanopyridine [932-35-4] or in 3 steps proceeding from commercially available 2-hydroxymethylpyridin-3-ol [14173-30-9]; 2) a process for preparing 4-hydroxy-1-(1H-imidazol-4-yl)butan-1-one, an intermediate from the synthesis of 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one (formula I), as described in WO 2002/040484, proceeding from N,N-dimethyl-2-(trialkylsilanyl)imidazole-1-sulphonamide by lithiation and subsequent reaction with a suitably protected 4-hydroxybutyraldehyde, followed by oxidation of the secondary alcohol, acid-induced deprotection of the imidazole and deprotection of the alcohol functionality; 3) a process which proceeds from 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine [38666-30-7], which is oxidized.

  6,7-二氢-5H-咪唑[1,5-a]吡啶-8-酮（I）可以通过以下方法高产率地得到：1）从适当保护的C-(3-羟基吡啶-2-基)甲胺开始，其胺基转化为甲酰胺，然后环化为咪唑[1,5-a]吡啶，并氢化为6,7-二氢-5H-咪唑[1,5-a]吡啶-8-酮，适当保护的C-(3-羟基吡啶-2-基)甲胺可以通过两步法从商业可得的3-羟基-2-氰基吡啶[932-35-4]制备，或者通过三步法从商业可得的2-羟甲基吡啶-3-醇[14173-30-9]制备；2）从N,N-二甲基-2-(三烷基硅基)咪唑-1-磺酰胺通过锂化和随后与适当保护的4-羟基丁醛反应，然后氧化二级醇，酸诱导去保护咪唑和去保护醇官能团，制备4-羟基-1-(1H-咪唑-4-基)丁酮，这是合成6,7-二氢-5H-咪唑[1,5-a]吡啶-8-酮（式I）的中间体，如WO 2002/040484中所述；3）从5,6,7,8-四氢咪唑[1,5-a]吡啶[38666-30-7]开始进行氧化的方法。
• CANNABINOID RECEPTOR MODULATORS
  申请人：Jones Robert M.

  公开号：US20120214766A1

  公开（公告）日：2012-08-23

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及公式Ia的某些化合物及其制药组合物，其调节大麻素CB2受体的活性。本发明还涉及公式Ia的某些化合物及其制药组合物，其调节CB1受体和CB2受体的活性。本发明的化合物和制药组合物适用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛，肌肉疼痛，牙痛，偏头痛和其他头痛，炎性疼痛，神经痛，由治疗副作用引起的疼痛和与骨关节炎相关的疼痛；过敏症；炎性过敏症；神经病性过敏症；急性疼痛感受；骨质疏松症；多发性硬化症相关痉挛；自身免疫疾病；过敏反应；中枢神经系统炎症；动脉粥样硬化；不良的免疫细胞活动和炎症；年龄相关的黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损伤；痴呆症；肌萎缩性侧索硬化症和帕金森病。
• Cannabinoid receptor modulators
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US11214548B2

  公开（公告）日：2022-01-04

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及某些调节大麻素 CB2 受体活性的式 Ia 化合物及其药物组合物。本发明还涉及某些能调节 CB1 受体和 CB2 受体活性的式 Ia 化合物及其药物组合物。本发明的化合物及其药物组合物用于治疗以下疾病的方法：疼痛，例如骨痛和关节痛、肌肉痛、牙痛、偏头痛和其他头痛、炎症性疼痛、神经性疼痛、作为治疗药物的不良反应出现的疼痛以及与骨关节炎相关的疼痛；痛觉减退；异动症；炎症性痛觉减退；神经性痛觉减退；急性痛觉；骨质疏松症；多发性硬化症相关的痉挛、自身免疫性疾病、过敏反应、中枢神经系统炎症、动脉粥样硬化、不想要的免疫细胞活性和炎症、老年性黄斑变性、咳嗽、白血病、淋巴瘤、中枢神经系统肿瘤、前列腺癌、阿尔茨海默病、中风引起的损伤、痴呆、肌萎缩性脊髓侧索硬化症和帕金森病。
• MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION
  申请人：Tibotec Pharmaceuticals Ltd.

  公开号：EP1697345B1

  公开（公告）日：2008-03-12